Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- CUDKOWICZ L., JACOBS J. H. Phenylbutazone (butazolidine) in the treatment of chronic arthritis. Lancet. 1953 Jan 31;1(6753):223–224. doi: 10.1016/s0140-6736(53)90891-5. [DOI] [PubMed] [Google Scholar]
- ETESS A. D., JACOBSON A. S. Fatality due to agranulocytosis following use of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 21;151(8):639–640. doi: 10.1001/jama.1953.02940080039009. [DOI] [PubMed] [Google Scholar]
- KUZELL W. C., SCHAFFARZICK R. W., BROWN B., MANKLE E. A. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc. 1952 Jun 21;149(8):729–734. doi: 10.1001/jama.1952.02930250011004. [DOI] [PubMed] [Google Scholar]
- NATHAN D. A., MEITUS M. L., CAPLAND L., LEV M. Death following phenylbutazone (butazolidin) therapy: report of a case. Ann Intern Med. 1953 Nov;39(5):1096–1103. doi: 10.7326/0003-4819-39-5-1096. [DOI] [PubMed] [Google Scholar]
- O'BRIEN D. J., STOREY G. Death from hypersensitivity due to phenylbutazone. Br Med J. 1954 Apr 3;1(4865):792–794. doi: 10.1136/bmj.1.4865.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
- STIFEL J. L., BURNHEIMER J. C. Agranulocytosis following administration of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 14;151(7):555–556. doi: 10.1001/jama.1953.02940070021007. [DOI] [PubMed] [Google Scholar]